Peijia Medical Limited (4WO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Peijia Medical Limited (4WO) has a cash flow conversion efficiency ratio of -0.096x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-235.16 Million ≈ $-274.93 Million USD) by net assets (€2.44 Billion ≈ $2.86 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Peijia Medical Limited balance sheet independence to measure how much of total assets are equity-financed.
Peijia Medical Limited - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Peijia Medical Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore 4WO operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Peijia Medical Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Peijia Medical Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yunnan Metropolitan Real Estate Development Co Ltd
SHG:600239
|
0.133x |
|
Morguard Real Estate Investment Trust
TO:MRT-UN
|
0.006x |
|
Guangdong TianYiMa Information Industry Co.Ltd.
SHE:301178
|
N/A |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX
|
-0.037x |
|
Bakkt Holdings Inc
NYSE:BKKT
|
-0.071x |
|
MCNEX Co. Ltd
KQ:097520
|
0.085x |
|
Vodafone Group PLC
LSE:VOD
|
0.163x |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Peijia Medical Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Peijia Medical Limited from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Peijia Medical Limited (4WO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.86 Billion ≈ $2.17 Billion |
€-20.89 Million ≈ $-24.42 Million |
-0.011x | -343.81% |
| 2024-12-31 | €2.04 Billion ≈ $2.39 Billion |
€-5.18 Million ≈ $-6.06 Million |
-0.003x | +99.09% |
| 2023-12-31 | €2.27 Billion ≈ $2.66 Billion |
€-630.91 Million ≈ $-737.60 Million |
-0.277x | -94.52% |
| 2022-12-31 | €2.64 Billion ≈ $3.08 Billion |
€-376.20 Million ≈ $-439.81 Million |
-0.143x | +1.32% |
| 2021-12-31 | €3.02 Billion ≈ $3.53 Billion |
€-436.37 Million ≈ $-510.16 Million |
-0.145x | -124.52% |
| 2020-12-31 | €2.81 Billion ≈ $3.29 Billion |
€-181.10 Million ≈ $-211.72 Million |
-0.064x | -135.03% |
| 2019-12-31 | €-558.21 Million ≈ $-652.60 Million |
€-102.59 Million ≈ $-119.94 Million |
0.184x | -55.23% |
| 2018-12-31 | €-94.34 Million ≈ $-110.29 Million |
€-38.73 Million ≈ $-45.28 Million |
0.411x | -- |
About Peijia Medical Limited
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products inc… Read more